Compumedics posts record FY26 revenue as director quits

Compumedics expects to report record FY26 shipped and invoiced revenue of about AUD $60.3 million, and has also disclosed the resignation of Non-executive Director Christopher R. Barys.

The revenue figure would represent about 18% growth from FY25, subject to audit.

FY26 sales orders reached about AUD $62.7 million, reflecting demand across the group's sleep, neurology, magnetoencephalography and connected platform operations. Earnings before interest, tax, depreciation and amortisation are also expected to rise, subject to audit.

Management said recurring revenue from Somfit and Nexus 360 software subscriptions increased by about 70% from the prior year, even though Somfit D has not yet been commercially released in the US market.

The result fell modestly short of the revised revenue guidance of about AUD $62 million to AUD $65 million issued in April. Compumedics attributed the shortfall mainly to timing, including delays to MEG shipment and invoicing and the slower path to a US launch for Somfit D.

Shipment delays

Disruptions in helium availability and pricing affected MEG shipment and installation timing more than expected. The issue has now been resolved, and recent MEG invoicing was completed in June.

Existing MEG orders continue to move through manufacturing and shipment. Compumedics described the delays as a matter of revenue timing rather than demand.

The update points to a mixed revenue base across hardware sales, service and supplies, and software subscriptions. Recurring revenue platforms made a larger contribution during FY26 as Compumedics worked to build a steadier income stream alongside equipment sales.

US rollout

Somfit D remains a focus as the group works towards a commercial release in the United States. Manufacturing commitments are now in place, and Compumedics said it is taking a deliberate approach to readiness and deployment.

The US home sleep testing market is a significant target, and the delayed launch has been one factor weighing on revenue conversion in the latest financial year. Even so, existing Somfit and Nexus 360 products helped lift subscription income.

Compumedics develops diagnostic technology used in sleep, brain and ultrasonic blood flow monitoring. Its operations include Neuroscan in the US and DWL Elektronishe Systeme in Germany, giving it a presence across the Americas, Europe, Asia Pacific and the Middle East.

Board change

Barys resigned by mutual agreement as Compumedics enters what it described as its next phase of development. He joined the board in September 2025 and brought experience in US medical technology, commercial strategy, strategic partnerships and capital markets.

During his time on the board, he supported the company's US growth and investor engagement work. The announcement did not name a replacement.

Comments from Compumedics and Barys followed the board change announcement.

"On behalf of the Board, I would like to thank Chris for his contribution to Compumedics during his time as a non-executive director. Chris brought valuable US MedTech, commercial and capital markets experience to the Board, and we appreciate his input and perspectives over the past nine months. We wish Chris well in his future endeavours," said David Burton, Executive Chairman of Compumedics.

"I am grateful for the opportunity to have served on the Board of Compumedics. I remain deeply impressed by the Company's vision, optimism and perseverance, and I look forward to following its continued global success," said Barys.

Growth focus

Across the business, Compumedics said its order book and sales pipeline remain healthy. The company is targeting another year of double-digit revenue growth in FY27 and expects EBITDA to grow faster than revenue, supported by order conversion, MEG activity and recurring software income.

For FY26, however, the clearest marker was the record revenue figure despite disruption from helium supply issues and the delayed US launch of Somfit D. Sales orders of about AUD $62.7 million and shipped and invoiced revenue of about AUD $60.3 million indicate that demand across the company's product lines remained intact.